ESMO 2017: Immunotherapy with durvalumab improves progression-free survival in patients with stage III NSCLC


  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Durvalumab, a new immunotherapy agent, improves progression-free survival in patients with locally advanced, unresectable stage III non-small-cell lung cancer according to the PACIFIC phase 3 trial.
  • Durvalumab, an inhibitor of programmed death-ligand 1, could be considered now as ...